Nanoparticles functionalized with Pep-1 as potential glioma targeting delivery system via interleukin 13 receptor α2-mediated endocytosis

Biomaterials

Volumn 35, Issue 22, 2014, Pages 5897-5907

  Wang, Baoyan ^a,b   Lv, Lingyan ^a   Wang, Zhongyuan ^a   Zhao, Yue ^a   Wu, Lin ^a   Fang, Xiaoling ^b   Xu, Qunwei ^a   Xin, Hongliang ^a  

^a NANJING MEDICAL UNIVERSITY   (China)

^b FUDAN UNIVERSITY   (China)

Author keywords

Blood tumor barrier (BTB); Glioma; Interleukin 13 receptor 2; Pep 1 peptide; Targeting nanoparticles

Indexed keywords

BLOOD; CELL CULTURE; DRUG DELIVERY; LIGANDS; MOLECULAR BIOLOGY; NANOPARTICLES;

CELLULAR ASSOCIATION; GLIOMA; INTERLEUKIN-13 RECEPTOR; INTRAVENOUS ADMINISTRATION; SIGNALING PATHWAYS; TARGETING DELIVERIES; TARGETING DRUG DELIVERIES; THERAPEUTIC EFFECTS;

TUMORS;

COUMARIN DERIVATIVE; INTERLEUKIN 13 RECEPTOR ALPHA2; LIGAND; MACROGOL; NANOPARTICLE; PEP 1 PEPTIDE; PEPTIDE; POLYGLACTIN; UNCLASSIFIED DRUG; COUMARIN; MERCAPTAMINE; PEP-1 PEPTIDE;

ABSORPTION; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BIOCOMPATIBILITY; BIODEGRADABILITY; CANCER THERAPY; COMPETITIVE INHIBITION; CONFOCAL LASER MICROSCOPY; CONJUGATION; CONTROLLED STUDY; DRUG DELIVERY SYSTEM; DRUG PENETRATION; DRUG TARGETING; DRUG UPTAKE; ENDOCYTOSIS; GLIOMA; GLIOMA CELL; IN VITRO STUDY; MALE; MOUSE; NONHUMAN; PARTICLE SIZE; PRIORITY JOURNAL; TUMOR SPHEROID; ZETA POTENTIAL; ANALOGS AND DERIVATIVES; ANIMAL; BRAIN; BRAIN NEOPLASMS; CELL LINE; CHEMISTRY; METABOLISM;

RATTUS;

ANIMALS; BRAIN; BRAIN NEOPLASMS; CELL LINE; COUMARINS; CYSTEAMINE; DRUG DELIVERY SYSTEMS; GLIOMA; INTERLEUKIN-13 RECEPTOR ALPHA2 SUBUNIT; MALE; MICE; NANOPARTICLES; PEPTIDES;

EID: 84899942122     PISSN: 01429612     EISSN: 18785905     Source Type: Journal    
DOI: 10.1016/j.biomaterials.2014.03.068     Document Type: Article

References (46)

1. Jain K.K. Use of nanoparticles for drug delivery in glioblastoma multiforme. Expert Rev Neurother 2007, 7(4):363-372.
2. 1-based MRI signal weighting approaches. Magn Reson Med 2008, 59(2):336-344.
3. Pardridge W.M. Drug targeting to the brain. Pharm Res 2007, 24(9):1733-1744.
4. Chekhonin V.P., Baklaushev V.P., Yusubalieva G.M., Belorusova A.E., Gulyaev M.V., Tsitrin E.B., et al. Targeted delivery of liposomal nanocontainers to the peritumoral zone of glioma by means of monoclonal antibodies against GFAP and the extracellular loop of Cx43. Nanomedicine 2012, 8(1):63-70.
5. Samoto K., Perng G.C., Ehtesham M., Liu Y., Wechsler S.L., Nesburn A.B., et al. Aherpes simplex virus type 1 mutant deleted for gamma 34.5 and LAT kills glioma cells invitro and is inhibited for invivo reactivation. Cancer Gene Ther 2001, 8(4):269-277.
6. Debinski W., Tatter S.B. Convection-enhanced delivery for the treatment of brain tumors. Expert Rev Neurother 2009, 9(10):1519-1527.
7. Demeule M., Currie J.C., Bertrand Y., Ché C., Nguyen T., Régina A., et al. Involvement of the low-density lipoprotein receptor-related protein in the transcytosis of the brain delivery vector angiopep-2. JNeurochem 2008, 106(4):1534-1544.
8. Inamura T., Nomura T., Bartus R.T., Black K.L. Intracarotid infusion of RMP-7, a bradykinin analog: a method for selective drug delivery to brain tumors. JNeurosurg 1994, 81(5):752-758.
9. McCarty D.M., DiRosario J., Gulaid K., Muenzer J., Fu H. Mannitol-facilitated CNS entry of rAAV2 vector significantly delayed the neurological disease progression in MPS IIIB mice. Gene Ther 2009, 16(11):1340-1352.
10. Maeda H., Wu J., Sawa T., Matsumura Y., Hori K. Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review. JControl Release 2000, 65(1-2):271-284.
11. Adams G.P., Weiner L.M. Monoclonal antibody therapy of cancer. Nat Biotechnol 2005, 23:1147-1157.
12. Brown K.C. Peptidic tumor targeting agents: the road from phage displaypeptide selections to clinical applications. Curr Pharm Des 2010, 16(9):1040-1054.
13. Lu Y., Low P.S. Folate-mediated delivery of macromolecular anticancer therapeutic agents. Adv Drug Deliv Rev 2002, 54(5):675-693.
14. Debinski W., Obiri N.I., Powers S.K., Pastan I., Puri R.K. Human glioma cells overexpress receptors for interleukin 13 and are extremely sensitive to a novel chimeric protein composed of interleukin 13 and Pseudomonas exotoxin. Clin Cancer Res 1995, 1:1253-1258.
15. Debinski W., Obiri N.I., Pastan I., Puri R.K. Anovel chimeric protein composed of interleukin 13 and Pseudomonas exotoxin is highly cytotoxic to human carcinoma cells expressing receptors for interleukin 13 and interleukin 4. JBiol Chem 1995, 270:16775-16780.
16. Husain S.R., Obiri N.I., Gill P., Zheng T., Pastan I., Debinski W., et al. Receptors for interleukin 13 on AIDS-associated Kaposi's sarcoma cells serves as a new target for a potent Pseudomonas exotoxin-based chimeric toxin protein. Clin Cancer Res 1997, 3:151-156.
17. Joshi B.H., Plautz G.E., Puri R.K. Interleukin-13 receptor a chain: a novel tumor-associated transmembrane protein in primary explants of human malignant gliomas. Cancer Res 2000, 60:1168-1172.
18. Puri R.K., Leland P., Obiri N.I., Husain S.R., Kreitman R.J., Haas G.P., et al. Targeting of interleukin-13 receptor on human renal cell carcinoma cells by a recombinant chimeric protein composed of interleukin-13 and a truncated form of Pseudomonas exotoxin A. Blood 1996, 87:4333-4339.
19. Kawakami K., Taguchi J., Murata T., Puri R.K. The interleukin-13 receptor α2 chain: an essential component for binding and internalization but not for interleukin-13-induced signal transduction through the STAT6 pathway. Blood 2001, 97:2673-2679.
20. Husain S.R., Kreitman R.J., Pastan I., Puri R.K. Interleukin-4 receptor-directed cytotoxin therapy of AIDS-associated Kaposi's sarcoma tumors in xenograft model. Nat Med 1999, 5:817-822.
21. Debinski W., Gibo D., Obiri N.I., Kealiher A., Puri R.K. Novel anti-brain tumor cytotoxins specific for cancer cells. Nat Biotech 1998, 16:449-453.
22. Husain S.R., Puri R.K. Interleukin-13 fusion cytotoxin as a potent targeted drug for AIDS-Kaposi's sarcoma xenograft. Blood 2000, 95:3506-3513.
23. Bera T.K., Viner E.B., Pastan I. Pharmacokinetics and antitumor activity of a bivalent disulphide-stabilized Fv immunotoxin with improved antigen binding to erbB2. Cancer Res 1999, 59:4018-4022.
24. Husain S.R., Joshi B.H., Puri R.K. Interleukin-13 receptor as a unique target for anti-glioblastoma therapy. Int J Cancer 2001, 92(2):168-175.
25. Béduneaua A., Saulniera P., Benoita J.P. Active targeting of brain tumors using nanocarriers. Biomaterials 2007, 28(33):4947-4967.
26. Pandya H., Gibo D.M., Garg S., Kridel S., Debinski W. An interleukin 13 receptor a 2-specific peptide homes to human Glioblastoma multiforme xenografts. Neuro Oncol 2012, 14(1):6-18.
27. Xin H.L., Jiang X.Y., Gu J.J., Sha X.Y., Chen L.C., Law k, et al. Angiopep-conjugated poly(ethylene glycol)-co-poly(e{open}-caprolactone) nanoparticles as dual-targeted drug delivery system for brain glioma. Biomaterials 2011, 32(18):4293-4305.
28. Wen Z.Y., Yan Z.Q., Hu K.L., Pang Z.Q., Cheng X.F., Guo L.R., et al. Odorranalectin-conjugated nanoparticles: preparation, brain delivery and pharmacodynamic study on Parkinson's disease following intranasal administration. JControl Release 2011, 151(2):131-138.
29. Boysen R.I., Hearn M.T. The metal binding properties of the CCCH motif of the 50 S ribosomal protein L36 from Thermus thermophilus. JPept Res 2001, 57(1):19-28.
30. Mura S., Hillaireau H., Nicolas J., Römer S.K., Droumaguet B.L., Delomeinie C., et al. Biodegradable nanoparticles meet the bronchial airway barrier: how surface properties affect their interaction with mucus and epithelial cells. Biomacromolecules 2011, 12(11):4136-4143.
31. Gao H.L., Qian J., Cao S.J., Yang Z., Pang Z.Q., Pan S.Q., et al. Precise glioma targeting of and penetration by aptamer and peptide dual-functioned nanoparticles. Biomaterials 2012, 33(20):5115-5123.
32. Becker K.P., Yu J. Status quo-standard-of-care medical and radiation therapy for glioblastoma. Cancer J 2012, 18(1):12-19.
33. Iacob G., Dinca E.B. Current data and strategy in glioblastoma multiforme. JMed Life 2009, 2(4):386-393.
34. Vehlowa A., Cordes N. Invasion as target for therapy of glioblastoma multiforme. Biochim Biophys Acta 2013, 1836(2):236-244.
35. Maeda H. The enhanced permeability and retention (EPR) effect in tumor vasculature: the key role of tumor-selective macromolecular drug targeting. Adv Enzyme Regul 2001, 41:189-207.
36. Xin H.L., Sha X.Y., Jiang X.Y., Zhang W., Chen L.C., Fang X.L. Anti-glioblastoma efficacy and safety of paclitaxel-loading Angiopep-conjugated dual targeting PEG-PCL nanoparticles. Biomaterials 2012, 33(32):8167-8176.
37. Jiang X.Y., Xin H.L., Ren Q.Y., Gu J.J., Zhu L.J., Du F.Y., et al. Nanoparticles of 2-deoxy-D-glucose functionalized poly(ethylene glycol)-co-poly(trimethylene carbonate) for dual-targeted drug delivery in glioma treatment. Biomaterials 2014, 35(1):518-529.
38. Dhanikula R.S., Argaw A., Bouchard J.F., Hildgen P. Methotrexate loaded polyether-copolyester dendrimers for the treatment of gliomas: enhanced efficacy and intratumoral transport capability. Mol Pharm 2008, 5(1):105-116.
39. Kawakami M., Kawakami K., Kasperbauer J.L., Hinkley L.L., Tsukuda M., Strome S.E., et al. Interleukin-13 receptor alpha2 chain in human head and neck cancer serves as a unique diagnostic marker. Clin Cancer Res 2003, 9(17):6381-6388.
40. Kornmann M., Kleeff J., Debinski W., Korc M. Pancreatic cancer cells express interleukin-13 and -4 receptors, and their growth is inhibited by Pseudomonas exotoxin coupled to interleukin-13 and -4. Anticancer Res 1999, 19(1):125-131.
41. Kioi M., Kawakami M., Shimamura T., Husain S.R., Puri R.K. Interleukin-13 receptor alpha2 chain: a potential biomarker and molecular target for ovarian cancer therapy. Cancer 2006, 107(6):1407-1418.
42. Gonzalez-Moreno O., Calvo A., Joshi B.H., Abasolo I., Leland P., Wang Z., et al. Gene expression profiling identifies IL-13 receptor alpha 2 chain as a therapeutic target in prostate tumor cells overexpressing adrenomedullin. Int J Cancer 2005, 114(6):870-878.
43. Madhankumar A.B., Slagle-Webb B., Mintz A., Sheehan J.M., Connor J.R. Interleukin-13 receptor-targeted nanovesicles are a potential therapy for glioblastoma multiforme. Mol Cancer Ther 2006, 5(12):3162-3169.
44. Nagothu K.K., Jaszewski R., Moragoda L., Rishi A.K., Finkenauer R., Tobi M., et al. Folic acid mediated attenuation of loss of heterozygosity of DCC tumor suppressor gene in the colonic mucosa of patients with colorectal adenomas. Cancer Detect Prev 2003, 27(4):297-304.
45. Xu S., Olenyuk B.Z., Okamoto C.T., Hamm-Alvarez S.F. Targeting receptor-mediated endocytotic pathways with nanoparticles: rationale and advances. Adv Drug Deliv Rev 2013, 65(1):121-138.
46. Minchinton A.I., Tannock I.F. Drug penetration in solid tumours. Nat Rev Cancer 2006, 6:583-592.